Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Stronger Sell Today ALDR ranks #5107 as SELL CANDIDATE #5107 Weaker Sell

ALDR stock forecast Alder BioPharmaceuticals

ALDR stock forecast

- Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate nearly 60% of patients reported very much or much improvement in most bothersome symptoms and in overall migraine status following two treatments with eptinezumab - - Study represents first time most bothersome symptom data has been reported in a chronic migraine prevention study - BOTHELL, Wash., May 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced a new analysis of patient-reported outcomes data from the PROMISE-2 Phase 3 clinical trial of eptinezumab for the prevention of chronic migraine. Eptinezumab is an investigational monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) administered by quarterly infusion for migraine prevention. The new analysis showed improvements in most bothersome migraine symptoms and patients' global impression of change in their migraine status by Month 1 after treatment, with improvements sustained or increased through the first and second quarterly infusion.

Read more

ALDR earnings call for the period ending March 31, 2019.

Read more

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Q1 2019 Earnings Conference Call May 02, 2019, 17:00 ET Company Participants Michael Horowicz - Stern Investor Rela

Read more

BOTHELL, Wash., April 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for eptinezumab. Eptinezumab is an investigational monoclonal antibody (mAb), administered intravenously, for migraine prevention targeting the calcitonin gene-related peptide (CGRP) and is Alder's lead commercial candidate. The company submitted its BLA on February 21, 2019 and continues to expect to receive a Prescription Drug User Fee Act (PDUFA) action date within 74 days following the submission. If the FDA grants approval of eptinezumab, Alder anticipates a Q1 2020 commercial launch. "Migraine is far more than a headache, it's a serious neurological disease with a debilitating impact to patients that can lead to other issues including depression, anxiety, and sleep disturbances," said Bob Azelby, Alder's president and chief executive officer. "The FDA's acceptance of our BLA is an important milestone, and the company remains focused on supporting the application review for the first quarterly infusion therapy for patients suffering from episodic and chronic migraine.

Read more

Jim Cramer chats with Alder Biopharmaceuticals CEO Robert Azelby to find out what the company is doing to address chronic migraine.

Read more

Both Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) and Acceleron Pharma Inc. (NASDAQ:XLRN) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommend

Read more

In trying to determine the current valuation of Alder BioPharmaceuticals, Inc. (NasdaqGM:ALDR) shares, we note that the Book to Market ratio of the shares stands at 0.096896. It’s commonly accepted

Read more

Investors might be trying to gauge which way shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) will swing over the next couple of quarters. In recent trading activity, the stock has been seen nea

Read more

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Alder

Read more

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) has been in the news after the price of the stock hit $13.31 at the conclusion of the most recent close. The stock is traded on NSDQ in the Medical sector

Read more

Tracking shares of Alder Biopharma (ALDR), we have noted that Span A is presently above Span B. Traders following this signal will be looking for signs of a bullish stock price shift. There are so man

Read more

The Current Ratio of Ain Holdings Inc. (TSE:9627) is 1.28. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all

Read more

Both Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) and Aevi Genomic Medicine Inc. (NASDAQ:GNMX) are Biotechnology companies, competing one another. We will

Read more

Sell-side equity analysts are typically working super hard to create realistic target prices for stocks that they cover. After a recent market scan, we can see that Alder BioPharmaceuticals, Inc. (NAS

Read more

Cancer Cachexia Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Cancer Cachexia industry with a focus on the Chinese market. T

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank